Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-16T21:38:39.789Z Has data issue: false hasContentIssue false

New presentation of familial medullary thyroid carcinoma in 87-year-old patient with high-risk RET proto-oncogene codon 620 mutation

Published online by Cambridge University Press:  04 September 2008

M K J Jaggard
Affiliation:
Department of Otolaryngology, St Mary's Hospital, London, UK
C MacRae
Affiliation:
Department of Otolaryngology, St Mary's Hospital, London, UK
S Ifeacho
Affiliation:
Department of Otolaryngology, St Mary's Hospital, London, UK
S Robinson
Affiliation:
Department of Endocrine Medicine, St Mary's Hospital, London, UK
N S Tolley*
Affiliation:
Department of Otolaryngology, St Mary's Hospital, London, UK
*
Address for correspondence: Mr N S Tolley, Department of Otolaryngology, St Mary's Hospital, Imperial College NHS Healthcare Trust, Praed Street, London W2 1NY, UK. E-mail: N.Tolley@imperial.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Objective:

We report a case of familial medullary thyroid carcinoma in an 87-year-old woman, despite the patient having a high-risk codon 620 mutation.

Method:

Medline and PubMed were searched for cases and literature reviews relating to the following keywords: ‘codon 620’, ‘medullary thyroid carcinoma’, ‘multiple endocrine neoplasia’ and ‘RET proto-oncogene’.

Results:

We report the case of an 87-year-old woman who presented with a goitre, later identified as medullary thyroid carcinoma. Genetic analysis revealed a RET proto-oncogene codon 620 mutation. Genetic testing has revolutionised the management of medullary thyroid carcinoma. The genetic basis of hereditary medullary thyroid carcinoma lies with the RET proto-oncogene. Several disease-causing mutations of this gene have been identified and their clinical prognosis described. The penetrance of these mutations is high; as such, carriers progress to develop medullary thyroid carcinoma at a young age. Mutations at the codon 620 position are classified as high-risk for early development of medullary thyroid carcinoma; thus, the current recommendation is for prophylactic thyroidectomy at five years of age.

Conclusions:

In this case, the progress of hereditary medullary thyroid carcinoma was unique, considering the late presentation of medullary thyroid carcinoma despite the presence of the high-risk RET proto-oncogene codon 620 mutation. The authors wish to highlight the importance of this case, as it may present a counter-argument to the current recommendations for early, prophylactic thyroidectomy in codon 620 mutation carriers in order to prevent early development of medullary thyroid carcinoma.

Information

Type
Clinical Records
Copyright
Copyright © JLO (1984) Limited 2008
Figure 0

Fig. 1Loci of the RET proto-oncogene associated with mutations causing medullary thyroid carcinoma.

Figure 1

Table IRecommended genotype-based management of medullary thyroid carcinoma*

Figure 2

Table IIRET proto-oncogene mutations and resultant RET protein alterations and clinical phenotypes7,12